In the manuscript "Multivariable Mendelian Randomization: the Use of Pleiotropic Genetic Variants to Estimate Causal Effects" (1), we commented on an analysis method recently used in the literature (2), which we referred to as a "regression-based method." We presented simulation results showing that the method had some weaknesses-in particular, not estimating the same parameter as that from a 2-stage least-squares analysis of individual-level data, and giving widely varying results when there were causal effects between the risk factors. A specific criticism of the method is that the uncertainty in the summarized associations (beta coefficients) used in the method is ignored.
We recently noticed a simple modification which can be made to the regression-based method that results in estimates which closely approximate those from a 2-stage least-squares analysis and remain stable when there are causal effects between the risk factors. In this letter, we describe this modification of the regression-based method (we refer to the modified method as a "weighted regression-based method") and repeat the simulations from the main paper using this modified method.
We assume that data are available on the associations of J uncorrelated genetic variants with each of K risk factors, such that the association estimate of variant j with risk factor k is X kj , with standard error σ Xkj , and the association estimate of variant j with the outcome is Y j , with standard error σ Yj . This notation matches that of our original article (1) . The weighted regressionbased method is performed by regression of the association estimates Y j on each of the X kj in a multivariable weighted regression model, using the σ When there is only 1 risk factor, the estimate from the weighted regression-based method is
and the corrected standard error is ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
These are exactly the estimate and the standard error from an inverse-variance-weighted summarized data method (4), also known informally as the "Toby Johnson" method (5). The equivalence of estimates from a 2-stage least-squares method and the weighted regression-based method can be demonstrated; details and software code are given in the Web Appendix (available at http://aje.oxfordjournals.org/).
Estimates from the weighted regression-based method for the simulation study in the original article (1) are given in Web Tables 1 and 2 . These tables replicate parts of Tables 1  and 2 from the original publication (1). Mean estimates from the weighted regression-based method equal those from the 2-stage least-squares method to within 0.001 in all scenarios considered. Mean standard errors, standard deviations of estimates, and the empirical power at a 5% significance level from the weighted regression-based method are also comparable to those from the other methods (Web Table 1 ). This contrasts with estimates from the unweighted regressionbased method, which differed substantially from those from a 2-stage least-squares method and had reduced power to detect a causal effect (see Table 1 in the original publication (1)). When there are causal effects between the risk factors (Web Table 2 ), the weighted regression-based method gives estimates that do not depend greatly on these causal effects (similarly to the other analysis methods).
The main criticism of the unweighted regression-based method is that the uncertainties in the genetic association estimates are not accounted for in the analysis. Through inclusion of the inverse-variance weights, evidence from more precisely estimated genetic associations receives more weight in the analysis. It would also be possible to weight the analyses using the inverse variance of the genetic associations with any of the risk factors; provided that the association estimates for that risk factor corresponding to each variant are based on the same sample size, the weighted estimates should be the same, although the standard errors would be incorrect.
In conclusion, we stand by our criticism of the unweighted regression-based method and the results of our original study (1), but we have now demonstrated a simple weighting of the regression-based method which produces estimates based on summarized data that are similar to those from the established 2-stage least-squares method based on individual-level data.
RE: "INCIDENCE OF DEMENTIA AMONG PARTICIPANTS AND NONPARTICIPANTS IN A LONGITUDINAL STUDY OF COGNITIVE AGING"
In a recent article, Knopman et al. (1) examined the impact of nonparticipation on estimates of dementia incidence. In their population-based study of cognitive aging, about 30% of approximately 4,400 eligible participants refused any participation but allowed review of their medical records. About 50% of all 1,967 study participants made all 4 scheduled follow-up visits; most of them made at least 2 visits (10-year follow-up in total) (1) . The numbers emphasize the importance of this topic. It is beyond all question that these people cannot simply be ignored.
Knopman et al. defined 3 different study groups (active, passive, and refusal) and compared their demographic characteristics, incidence rates of dementia, and cumulative dementia incidence. Based on the results of their analysis, they concluded that nonparticipation had little or no impact on dementia incidence rates (1) . However, the data reported in their article let us assume that 2 other important aspects were not addressed: first, competing risks and, second, interval censoring.
In the article, dementia incidence is reported as 19.6 per 1,000 person-years in the active + passive group and as 23.2 per 1,000 person-years in the refusal group. The "Total" section of Table 2 (1, p. 419) gives identical numbers but as percentages, which is presumably a typographical error. However, regarding the first aspect, a "Kaplan-Meier plot" is presented in Figure 2 (1, p. 420), where cumulative dementia incidence exceeds 50% for persons above age 95 years. This plot suffers from the fact that a "classical" survival analysis approach is used without consideration of death before dementia onset as a competing risk, which is particularly relevant for an aging cohort. It is well-known that the resulting quantity cannot be interpreted as cumulative incidence (for example, see references 2-6). Specifically, Andersen et al. (4) provided an in-depth explanation of incidence estimation under competing risks and illustrated it using data from the European Group for Blood and Marrow Transplantation. Correspondingly, in their Figure 3 (4, p. 865), they showed the cumulative incidence of relapse resulting from a competing-risks model and compared it with the respective "Kaplan-Meier plot" (more precisely, 1 minus the KaplanMeier estimate). The latter grossly overestimates cumulative relapse incidence, since over the course of time all competing nonrelapse mortality cases were right-censored. In dementia research, this is most relevant for older ages, where death without disease is a natural competitor.
Regarding the second aspect, because the diagnosis was made at intermittent follow-up visits, age of dementia onset is interval-censored. Therefore, disease status before death is unknown for participants who were dementia-free at the last visit before death. In Knopman et al.'s article, it seems that age at dementia was right-censored for participants who died before a potential dementia diagnosis, which may underestimate disease incidence since those potential dementia cases were not recorded (7). In dementia research, this problem is most relevant for younger ages, where death due to disease prevails.
So, the correct model here is an illness-death model for interval-censored data (see Figure 1) , which also accounts for the probability of developing the disease between the last visit and death (7). Adequate estimation of age-specific cumulative dementia incidence accounting for both of these aspects can be performed-for example, with the R (8) package SmoothHazard (9), which is designed to fit exactly those kinds of data.
These considerations have also been discussed in the presence of risk factors affecting disease and death, where the 
